Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis-Reference-Cited by-同舟云学术

Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis

Published:2016-04-05 Issue:9 Volume:88 Page:1576-1586
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:J. Med. Virol.

Author:

An Jihyun¹,Shim Ju Hyun¹,Kim Seon-Ok²,Choi Jonggi¹,Kim Sang-We³,Lee Danbi¹,Kim Kang Mo¹,Lim Young-Suk¹,Lee Han Chu¹,Chung Young-Hwa¹,Lee Yung Sang¹,Suh Dong Jin⁴

Affiliation:

1. Department of Gastroenterology, Asan Liver Center; Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea

2. Department of Biostatistics and Clinical Epidemiology; Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea

3. Department of Oncology; Asan Medical Center; University of Ulsan College of Medicine; Seoul Republic of Korea

4. Department of Internal Medicine; Vievisnamuh Hospital; Seoul Republic of Korea

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jmv.24512/fullpdf

Reference31 articles.

1. Epidemiology of hepatitis B in Europe and worldwide;Alter;J Hepatol,2003

2. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment;Chen;J Hepatol,2014

3. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease;Chen;Liver Int,2013

4. Recent US food and drug administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg;Di Bisceglie;Hepatology,2015

5. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis;Dong;J Clin Virol,2013

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis;Seminars in Oncology;2024-08

2. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy;Virology Journal;2024-04-03

3. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation;Journal of Infection and Public Health;2023-11

4. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era;World Journal of Gastroenterology;2023-09-07

5. HBsAg (−)/HBsAb (−)/HBeAg (−)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B‐cell lymphoma receiving rituximab based immunochemotherapy;Journal of Medical Virology;2023-02